You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動|荃信生物升超8%創近一個月新高 核心產品QX005N的開發及潛在商業化推進
格隆匯 07-31 14:07
荃信生物-B(2509.HK)午後升8.47%,報26.9港元,創近一個月新高。該股近三個交易日已累計升超26%。消息面上,荃信生物近日宣佈,與華東醫藥全資子公司杭州中美華東再度聯手,雙方就荃信生物自主研發的QX005N(重組人源化IL-4Rα單克隆抗體)注射液簽署合作開發及市場推廣服務協議。公吿稱,與一家在全國擁有強大開發及商業化能力以及充足臨牀資源的大型醫藥公司合作以加快開發標的產品符合集團的最佳利益。此舉亦符合行業慣例,併為集團帶來商業利益,因為與中美華東的合作有利於標的產品充分拓展多適應症,釋放產品價值;加快標的產品現有III期臨牀試驗的開發進度,併為集團帶來更多資金支持。中泰國際曾發報吿指,重點關注核心產品QX005N、QX002N及2024年有望上市的QX001S針對的特應性皮炎、強直性關節炎藥物、中重度斑塊型銀屑病的生物製劑需求前景,認為特應性皮炎生物製劑與銀屑病藥物需求增長將較快。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account